We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Single-Cell Proteomics of Localized Prostate Cancer Defines Disease Heterogeneity

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of LeicaBiosystems)
Image: BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of LeicaBiosystems)

Prostate cancer affects about 12.6% of men over the course of their lives, and while most individuals with localized disease can be cured, disease does recur in a small number of patients. The treatment of localized prostate cancer is based on clinicopathological information including Gleason score, prostate-specific antigen (PSA) levels, stage, and patient age.

Several potential biomarkers including gene fusions, mutations, epigenetic heterogeneity, and proteins have been studied. Technological advances in proteomics now allow both exploration of the proteome for biomarkers and assessment of the heterogeneity of biomarker expression. However, analysis of a whole tissue core misses important cell-to-cell variability.

An international team of clinical scientists collaborating with the University of Zürich (Zürich, Switzerland) collected samples from a cohort of 58 prostate cancer patients that included 24 patients with grade II disease, 22 with grade III, and 12 with grade V disease. For 17 patients, they also collected and analyzed adjacent benign prostatic tissue. The single-cell mass cytometry analysis they used relied on a panel of 36 metal-tagged antibodies that recognized surface markers, enzymes, transcription factors, and markers of functional readouts. In all, they analyzed more than 1.67 million cells.

For the dissociation of tissues to single cells, the tissue was minced using surgical scalpels and further disintegrated using the Tumor Dissociation Kit, human)and the gentleMACS Dissociator (Miltenyi Biotech, Bergisch Gladbach, Germany). The team also performed mass cytometry barcoding, antibodies and antibody labeling, antibody staining and mass cytometry data collection and data were acquired on an upgraded Helios CyTOF 2 mass cytometer (Fluidigm, South San Francisco, CA, USA). Automated platforms were used for in situ protein expression analyses of CD15, and CD3 (Leica Bond-Max, LeicaBiosystems, Deer Park, IL, USA).

The investigators fed their data into the Franken computational pipeline, an unsupervised, single-cell clustering approach they developed. Franken identified 55 different cell clusters, which the team organized in a set of 33 metaclusters, consisting of 14 epithelial, 16 immune, one stromal, and one endothelial cell clusters as well as a cluster lacking most markers in the panel. This set, they said, reflects the main cell-type compartments in the prostate. Luminal cells, for instance, were the most abundant cell type, followed by T cells.

There was, the scientists noted, overlap in the cell phenotypes found among tumor and associated benign tissue, though they diverged in their immune landscape and in rare phenotypes present. Two T cell clusters, dubbed TC03 and TC04, representing apoptotic and proliferating T cells, respectively, were enriched among tumor samples, as were two macrophage clusters. They additionally noted that two phenotypes enriched in high-grade patients express CD15, which is involved in cell adhesion and migration and has been implicated in other tumor types as having stem-like potential, suggesting it could be a marker of aggressive disease.

The authors concluded that they had found that tumor and non-tumor regions differed in rare cell types. This made it difficult to employ bulk RNA sequencing in survival analysis as well. Furthermore, they discovered a rare proliferating macrophage and T cell subpopulations as well as an uncommon CD15+ cell type that was enriched in tumor and advanced disease. The study was published on April 19, 2022 in the journal Cell Reports Medicine.

Related Links:
University of Zürich 
Miltenyi Biotech 
Fluidigm 
LeicaBiosystems 

Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Flu Test
ID NOW Influenza A & B 2
New
Thyroid ELISA Kit
AESKULISA a-TPO

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more